Abstract
Background: Anaphylaxis is a systemic and severe allergic reaction, which can be fatal. The first-line treatment of choice, according to international guidelines, is intramuscular adrenaline. However, different studies show that the performance of health professionals managing anaphylaxis is often inadequate
Objective: To assess the current resources available in Latin American countries for the diagnosis and treatment of anaphylaxis.
Methods: Online survey promoted by the Latin American Society of Allergy and Immunology to representatives of the national allergy societies of Latin American countries.
Results: Responses were received from 10 countries out of the 14 countries invited to participate. Only five of the countries have clinical practice guidelines in anaphylaxis. Adrenaline autoinjectors are available only in two countries, Argentina and Brazil, but are not subsidized by public health systems. In all countries, adrenaline is available in ampoules, which is the presentation usually prescribed to patients for self-administration. The use of adrenaline was estimated to be less than 50 % of cases in five countries, while antihistamines and corticosteroids are almost always used. The determination of serum tryptase is possible in some health centers, often private, in five of the countries surveyed.
Conclusion: It is necessary to improve resources related to the diagnosis and management of anaphylaxis in Latin American countries.
References
Simons FER, Ardusso LRF, Bilò MB, El-Gamal YM, Ledford, Ring J, et al. World allergy organization guidelines for the assessment and management of anaphylaxis. World Allergy Organ J. 2011;4(2):13-37. DOI: http://dx.doi.org/10.1097/WOX.0b013e318211496c
Ansotegui IJ, Sánchez-Borges M, Cardona V. Current trends in prevalence and mortality of anaphylaxis. Curr Treat Options Allergy. 2016;3(3):205-211. DOI: http://dx.doi.org/10.1007/s40521-016-0094-0
Tejedor-Alonso MA, Moro-Moro M, Múgica-García M V. Epidemiology of anaphylaxis. Clin Exp Allergy. 2015;45(6):1027-1039. DOI: http://dx.doi.org/10.1111/cea.1241
Plumb B, Bright P, Gompels MM, Unsworth DJ. Correct recognition and management of anaphylaxis: Not much change over a decade. Postgrad Med J. 2015;91(1071):3-7. DOI: http://dx.doi.org/10.1136/postgradmedj-2013-132181
Altman AAM, Camargo CJA, Simons FER, Lieberman P, Sampson HA, Schwartz LB, et al. Anaphylaxis in America: A national physician survey. J Allergy Clin Immunol. 2015;135(3):830-833. DOI: http://dx.doi.org/10.1016/j.jaci.2014.10.049
Solé D, Ivancevich JC, Cardona V. Knowledge of anaphylaxis among Ibero-American physicians: Results of the Ibero-American Online Survey for Physicians on the management and treatment of anaphylaxis (IOSPTA)-Latin American society of Allergy, Asthma & Immunology (LASAAI). J Investig Allergol Clin Immunol. 2013;23(6):441-443. Disponible en: http://www.jiaci.org/summary/vol23-issue6-num1060
Cardona Dahl V; Grupo de Trabajo de la Guía GALAXIA de Actuación en Anafilaxia. Guía de actuación en anafilaxia. Med Clin. 2011;136(8):349-355. DOI: http://dx.doi.org/10.1016/j.medcli.2010.10.003
Lieberman P, Nicklas RA, Oppenheimer J, Kemp SF, Lang DM, Bernstein DI, et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol. 2010;126(3):477-480. DOI: http://dx.doi.org/10.1016/j.jaci.2010.06.022
Simons FER, Ardusso LR, Bilò MB, Cardona V, Ebisawa M, El-Gamal YM, et al. International consensus on (ICON) anaphylaxis. World Allergy Organ J. 2014;7(1):9. DOI: http://dx.doi.org/10.1186/1939-4551-7-9
World Health Organization. [Sitio web]. WHO model lists of essential medicines. Geneve: World Health Organization; 2016. Disponible en http://www.who.int/medicines/publications/essentialmedicines/en/#
Tanno LK, Ganem F, Demoly P, Toscano CM, Bierrenbach AL. Undernotification of anaphylaxis deaths in Brazil due to difficult coding under the ICD-10. Allergy. 2012;67(6):783-789. DOI: http://dx.doi.org/10.1111/j.1398-9995.2012.02829
Tanno LK, Bierrenbach AL, Calderon MA, Sheikh A, Simons FE, Demoly P, et al. Decreasing the undernotification of anaphylaxis deaths in Brazil through the International Classification of Diseases (ICD)-11 revision. Allergy. 2017;72(1):120-125. DOI: http://dx.doi.org/10.1111/all.13006
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2017 Revista Alergia México